In the published article, there was an error in the legend for Figure 5 as published. The legend was incorrectly recorded as: “The receiver operating characteristic (ROC) curves The area under the curve (AUC) was 0.795 (95% CI: 0.747–0.843) in the training set, 0.809 (95% CI: 0.738–0.880) in the validation set, and 0.705 (95% CI: 0.651–0.759) in the predictive model only including baseline indicators.”
The corrected legend appears below:
“The receiver operating characteristic (ROC) curves The area under the curve (AUC) was 0.792 (95% CI: 0.744–0.839) in the training set, 0.785 (95% CI: 0.709–0.862) in the validation set, and 0.697 (95% CI: 0.652–0.742) in the predictive model only including baseline indicators.”
Figure 5
The receiver operating characteristic (ROC) curves The area under the curve (AUC) was 0.792 (95% CI: 0.744–0.839) in the training set, 0.785 (95% CI: 0.709–0.862) in the validation set, and 0.697 (95% CI: 0.652–0.742) in the predictive model only including baseline indicators.
In the published article, there was also an error in which the incorrect values were written. A correction has been made to Abstract, Results. This sentence previously stated:
“The nomogram had an area under the receiver operating characteristic curve (AUC) of 0.795 (95% CI: 0.747–0.843)”
The corrected sentence appears below:
“The nomogram had an area under the receiver operating characteristic curve (AUC) of 0.792 (95% CI: 0.744–0.839)”
The authors apologize for these errors and state they this does not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
breast cancer, neoadjuvant systemic therapy, efficacy indicators, pathologic complete response, nomogram
Citation
Shi W, Huang X, Wang Y, Wan X, He J, Xu Y, Zhang W, Chen R, Xu L, Zha X and Wang J (2022) Corrigendum: A novel nomogram containing efficacy indicators to predict axillary pathologic complete response after neoadjuvant systemic therapy in breast cancer. Front. Endocrinol. 13:1109390. doi: 10.3389/fendo.2022.1109390
Received
27 November 2022
Accepted
06 December 2022
Published
19 December 2022
Volume
13 - 2022
Edited and reviewed by
Cinthia Rosemblit, CONICET Institute for Biomedical Research (BIOMED), Argentina
Updates
Copyright
© 2022 Shi, Huang, Wang, Wan, He, Xu, Zhang, Chen, Xu, Zha and Wang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jue Wang, wangjue200011@njmu.edu.cn; Xiaoming Zha, njzhaxm@njmu.edu.cn
†These authors have contributed equally to this work
This article was submitted to Cancer Endocrinology, a section of the journal Frontiers in Endocrinology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.